OnKure Therapeutics (OKUR)
Develops mutation-selective PI3Kα medicines for cancer and vascular anomalies.
$2.95
vs last close−0.16 (−5.00%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 86.25% | 34.93M shares | |
|---|---|---|---|
| 76 holders · as of Jun 30, 2026 | |||
| Insiders | 8.28% | 3.35M shares | |
| 6 holders · as of Jun 24, 2026 | |||
| Other | 5.47% | 2.21M shares | |
| remainder | |||
40.50M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
1 position filed across a stock split leaves its adjustment unstated and stays out of the bar.
13F, as of Jun 30, 2026
76 holders · 34.93M shares · 33 new positions · 54 increased · 9 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 4.00M | 9.87% | 0 | Aug 14, 2026 |
| BVF Inc/IL | 3.24M | 7.99% | +1.26M | Aug 14, 2026 |
| Acorn Capital Advisors, LLC | 2.84M | 7.01% | 0 | Aug 14, 2026 |
| Stepstone Group LP | 2.66M | 6.57% | 0 | Aug 13, 2026 |
| Adar1 Capital Management, LLC | 2.24M | 5.53% | −196.3K | Aug 14, 2026 |
| Vivo Capital, LLC | 1.93M | 4.76% | 0 | Aug 14, 2026 |
| Vestal Point Capital, LP | 1.83M | 4.51% | −14.1K | Aug 14, 2026 |
| BlackRock, Inc. | 1.50M | 3.70% | +1.45M | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Anders Hoveincl. Acorn Capital Advisors GP 2, LLC, Acorn Bioventures, L.P. +2 more | 22.10% | 2.84M | 13D | May 30, 2025 |
| AI Biotechnology LLCincl. Len Blavatnik, Access Industries Management, LLC +1 more | 19.99% | 9.09M | 13D | Apr 7, 2026 |
| RA Capital Management, L.P. | 9.90% | 4.04M | 13G | Apr 7, 2026 |
| StepStone Group LP | 6.60% | 2.66M | 13G | Apr 7, 2026 |
| Shay Capital LLC | 6.30% | 810.2K | 13G | May 29, 2025 |
| ADAR1 Capital Management, LLC | 6.00% | 2.43M | 13G | May 15, 2026 |
| Trails Edge Capital Partners, LP | 6.00% | 2.41M | 13G | Apr 7, 2026 |
| Prosight Management, LP | 5.80% | 745.6K | 13G | Nov 28, 2025 |
| Cantor Fitzgerald Securities | 5.20% | 669.5K | 13G | Aug 14, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 22, 2026 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 303 | $4.40 | 18,802 |
| Jun 22, 2026 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 86 | $4.40 | 11,247 |
| Mar 23, 2026 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 301 | $4.16 | 16,000 |
| Mar 23, 2026 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 86 | $4.16 | 7,333 |
| Dec 22, 2025 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 302 | $2.97 | 16,301 |
| Dec 22, 2025 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 87 | $2.97 | 7,419 |
| Sep 22, 2025 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 303 | $2.62 | 12,603 |
| Sep 22, 2025 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 88 | $2.62 | 3,506 |
House and Senate disclosures
Not reported.